We are live on ! Find out more
PAWC

P.A.W. Capital Portfolio holdings

AUM $128M
1-Year Est. Return 46.78%
This Fund
S&P 500
This Quarter Est. Return
-7.19%
1 Year Est. Return
+46.78%
3 Year Est. Return
+67.91%
5 Year Est. Return
+65.57%
10 Year Est. Return
+1,466.09%
AUM
$79.7M
AUM Growth
-$14.5M
Cap. Flow
-$4.73M
Cap. Flow %
-5.94%
Top 10 Hldgs %
43.87%
Holding
70
New
4
Increased
16
Reduced
25
Closed
8

Top Buys

Rank Stock Value
1
VRTU
Virtusa Corporation
VRTU
+$2.28M
2
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$1.99M
3
CTLP
Cantaloupe
CTLP
+$897K
4
JPM icon
JPMorgan Chase
JPM
+$639K
5
MSFT icon
Microsoft
MSFT
+$536K

Top Sells

Rank Stock Value
1
MNDT
Mandiant, Inc. Common Stock
MNDT
+$1.62M
2
CARB
Carbonite Inc
CARB
+$1.19M
3
CLLS
Cellectis
CLLS
+$1.13M
4
ARCC icon
Ares Capital
ARCC
+$993K
5
TCPC icon
BlackRock TCP Capital
TCPC
+$976K

Sector Composition

Rank Sector Weight
1 Technology 36.8%
2 Healthcare 15.92%
3 Communication Services 14.15%
4 Consumer Staples 10.92%
5 Industrials 8.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
T icon
26
AT&T
T
$169B
$714K 0.9%
33,100
– –
CTLP
27
DELISTED
Cantaloupe
CTLP
$700K 0.88%
180,000
+170,945
+1,888% +$897K
RDS.A
28
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
$699K 0.88%
12,000
– –
MRK icon
29
Merck
MRK
$326B
$688K 0.86%
9,432
-1,048
-10% -$74K
VZ icon
30
Verizon
VZ
$201B
$675K 0.85%
12,000
-3,000
-20% -$170K
PEP icon
31
PepsiCo
PEP
$195B
$663K 0.83%
6,000
– –
PFE icon
32
Pfizer
PFE
$144B
$655K 0.82%
15,810
-1,054
-6% -$43.8K
ABT icon
33
Abbott
ABT
$187B
$651K 0.82%
9,000
-1,000
-10% -$70.3K
JNJ icon
34
Johnson & Johnson
JNJ
$643B
$645K 0.81%
5,000
-500
-9% -$69.7K
PG icon
35
Procter & Gamble
PG
$347B
$643K 0.81%
7,000
-1,000
-13% -$89.4K
DD icon
36
DuPont de Nemours
DD
$19B
$642K 0.81%
4,739
+790
+20% +$113K
ARCC icon
37
Ares Capital
ARCC
$13.7B
$623K 0.78%
40,000
-60,000
-60% -$993K
KO icon
38
Coca-Cola
KO
$380B
$616K 0.77%
13,000
-2,000
-13% -$95.7K
GLMD icon
39
Galmed Pharmaceuticals
GLMD
$4.1M
$615K 0.77%
500
– –
GSK icon
40
GSK
GSK
$108B
$611K 0.77%
12,800
– –
BP icon
41
BP
BP
$107B
$607K 0.76%
16,508
+798
+5% +$31.9K
ABBV icon
42
AbbVie
ABBV
$465B
$599K 0.75%
6,500
– –
CVX icon
43
Chevron
CVX
$374B
$598K 0.75%
5,500
+500
+10% +$57.9K
OHI icon
44
Omega Healthcare
OHI
$15.4B
$598K 0.75%
17,000
-3,000
-15% -$104K
MO icon
45
Altria Group
MO
$125B
$593K 0.74%
12,000
– –
TCPC icon
46
BlackRock TCP Capital
TCPC
$274M
$587K 0.74%
45,000
-70,000
-61% -$976K
JPM icon
47
JPMorgan Chase
JPM
$950B
$586K 0.73%
+6,000
New +$639K
KHC icon
48
Kraft Heinz
KHC
$32.4B
$560K 0.7%
13,000
+3,000
+30% +$155K
XOM icon
49
ExxonMobil
XOM
$634B
$546K 0.68%
8,000
+500
+7% +$39.2K
CCXI
50
DELISTED
ChemoCentryx, Inc.
CCXI
$546K 0.68%
50,000
-40,000
-44% -$422K
1
2
3

Similar funds

PIA
Prakash Investment Advisors Andover, Massachusetts $128M AUM 44.06% 1-Year Est. Return
BC
Barnett & Company Chattanooga, Tennessee $129M AUM 14.9% 1-Year Est. Return
TP
TenCore Partners New York $129M AUM 5.67% 1-Year Est. Return
VAM
Vienna Asset Management Saratoga, California $129M AUM 12.64% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return
DV
DAG Ventures Palo Alto, California $129M AUM
AAMG
AMG Asset Management Group Cartersville, Georgia $129M AUM

P.A.W. Capital's Q4 2018 Portfolio in Review

As of Q4 2018, P.A.W. Capital held 70 positions worth $79.7M, down 15% from $94.2M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

P.A.W. Capital withdrew a net $4.73M in Q4 2018, closing 8 positions and reducing 25 holdings. Its most notable exit was Cellectis, an estimated $1.13M position sold in full.

By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 32% a quarter earlier, followed by Healthcare and Communication Services.

Against the trend, P.A.W. Capital opened a new position in JPMorgan Chase worth $586K.

  • P.A.W. Capital's largest Q4 2018 buy was JPMorgan Chase: 6,000 shares worth $586K.
  • P.A.W. Capital added most to Virtusa Corporation in Q4 2018, an estimated $2.28M increase.
  • P.A.W. Capital's biggest Q4 2018 reduction was Mandiant, Inc. Common Stock, cutting an estimated $1.62M.
  • P.A.W. Capital fully exited Cellectis in Q4 2018, selling an estimated $1.13M.
  • P.A.W. Capital's ten largest holdings make up 44% of its $79.7M portfolio in Q4 2018.
  • P.A.W. Capital opened 4 new positions and closed 8 in Q4 2018.
  • P.A.W. Capital's portfolio value fell 15% quarter-over-quarter to $79.7M.

Based on P.A.W. Capital's 13F filing for Q4 2018, filed 6 Feb 2019.